Overview

Efficacy and Safety Study of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or

Status:
Completed

Trial end date:
2020-08-17

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare the efficacy of maribavir to investigator-assigned anti-Cytomegalovirus (CMV) therapy in CMV viremia clearance in transplant recipients who are refractory or resistant to prior anti-CMV treatment.

Phase:

Phase 3

Details

Lead Sponsor:

Shire

Treatments:

Cidofovir
Foscarnet
Ganciclovir
Ganciclovir triphosphate
Maribavir
Valganciclovir